---
title: Pilot Success Metrics for R&D AI
doc_type: metrics
owner: R&D AI Product Owner
status: draft
company: ACME Pharma
confidentiality: Internal
scenario: AI in Research and Development planning evidence
Document_File_Name: 26_pilot_success_metrics.md
IIA_Type: GOV
IIA_Type_Rational: The document defines proposed success metrics for the R&D AI pilot,
  serving as a governance artifact that will guide go/no-go decisions and ensure balanced
  evaluation of productivity, quality, safety, and control.
Quality_Rating: H
Relevance_Score: H
Fact: The document proposes a set of pilot success metrics for ACME Pharma's R&D AI
  initiative. It warns that productivity metrics alone are insufficient and that safety,
  traceability, and review quality must be included. The balanced metrics cover productivity,
  evidence quality, scientific review, safety, data quality, adoption, and supplier
  control. Specific measures include time saved in literature summaries, percentage
  of outputs with reviewable source references, reviewer ratings, number of unsupported
  claims detected, escalations for data classification or IP issues, and blocked restricted-data
  uploads. The document states that the team should not use simple output volume or
  time saved as the primary success measure. It emphasizes that if speed is rewarded
  without evidence quality, the pilot could create polished but weak scientific material.
  The metrics are intended to support go/no-go decisions, not just show adoption.
  The document is in draft status and owned by the R&D AI Product Owner.
Summary: 'The document outlines proposed success metrics for ACME Pharma''s R&D AI
  pilot, emphasizing a balanced approach beyond productivity. It lists initial metrics
  including time saved, source reference coverage, reviewer ratings, unsupported claims,
  escalations, rejected requests, adoption, and feedback-driven changes. A warning
  stresses that productivity alone is insufficient and that safety, traceability,
  and review quality must be part of success. A table categorizes metrics into productivity,
  evidence quality, scientific review, safety, data quality, adoption, and supplier
  control, with example measures and their importance. Another warning cautions against
  using simple output volume or time saved as the primary measure, as speed without
  evidence quality could yield polished but weak scientific material. The document
  further details metric categories: value metrics like time saved and faster identification
  of contradictory evidence; quality metrics like source-grounding accuracy and reviewer
  acceptance rate; control metrics covering intake, data classification, access review,
  supplier review, and output-review evidence; adoption metrics tracking active users,
  repeat usage, and use-case expansion; and risk metrics including policy exceptions,
  restricted-data warnings, and overdue reviews. It concludes that the metrics are
  intended to support go/no-go decisions, not merely demonstrate adoption, and warns
  that high usage with weak source grounding or uncl...'
Section_Context: Governance framework
IIA_Relevance_Explanation: The document defines proposed success metrics for the R&D
  AI pilot, serving as a governance artifact that will guide go/no-go decisions and
  ensure balanced evaluation of productivity, quality, safety, and control.
IIA_Relevance: H
IIA_Confidence: H
Notes: 'Auto-derived categorization: The document defines proposed success metrics
  for the R&D AI pilot, serving as a governance artifact that will guide go/no-go
  decisions and ensure balanced e...'
---

# Pilot Success Metrics for R&D AI


## Proposed metrics

- Time saved in preparing literature summaries.
- Percentage of outputs with reviewable source references.
- Reviewer rating of usefulness and correctness.
- Number of unsupported claims detected by reviewers.
- Number of escalations for data classification, IP, Legal, Privacy, or Security.
- Number of rejected or unsafe requests.
- User adoption within approved pilot group.
- Number of changes made because of reviewer feedback.

## Warning

Productivity metrics alone are not sufficient. The pilot could save time while increasing confidentiality, scientific integrity, or IP risk. Success should include safety, traceability, and review quality.

## Balanced pilot metrics

| Metric category | Example measure | Why it matters |
|---|---|---|
| Productivity | Median time to prepare literature briefing | Shows whether the pilot solves a real workflow problem |
| Evidence quality | Percentage of material claims with reviewed source links | Prevents speed from replacing traceability |
| Scientific review | Percentage of accepted outputs with reviewer rationale | Tests whether human oversight is substantive |
| Safety | Blocked restricted-data uploads and escalations | Shows whether guardrails are active |
| Data quality | Retrieval misses found during reviewer checks | Measures evidence completeness risk |
| Adoption | Approved-tool use versus shadow-tool use | Shows whether governance is usable |
| Supplier control | Timely review of support access and change notices | Tests third-party operational discipline |

## Metric warning

The team should not use simple output volume or time saved as the primary success measure. If speed is rewarded without evidence quality, the pilot could create polished but weak scientific material.

## Metric categories

Pilot success metrics cover value, quality, control, adoption, and risk indicators. Value metrics include time saved in literature triage, reduction in duplicated review work, and faster identification of contradictory evidence. Quality metrics include source-grounding accuracy, reviewer acceptance rate, rate of unsupported claims, and frequency of useful challenge comments. Control metrics include completion of intake, data classification, access review, supplier review, and output-review evidence.

Adoption metrics track active users, repeat users, workspace creation, output exports, and use-case expansion. Risk metrics track policy exceptions, restricted-data warnings, incident reports, overdue reviews, model-change events, and pilots operating past their approved window.

## Use in governance decisions

The metrics are meant to support go/no-go decisions, not just show adoption. A pilot with high usage but weak source grounding or unclear supplier restrictions should not automatically move to routine use. Conversely, a low-volume pilot may still be valuable if it addresses a high-risk workflow with strong controls.

The audit should test whether success metrics are defined before pilots begin and whether governance forums actually use them. Retrospective metrics chosen after a pilot succeeds are weaker evidence.

## Detailed audit scenario and sample evidence

For audit planning, this artifact would normally be supported by several underlying records rather than read in isolation. Expected supporting evidence includes the accountable owner, approval date, related use-case ID, related system ID, affected R&D functions, data classes permitted, supplier involvement, intended decision impact, and the operating procedure or workflow that tells users what to do. A mature record would also show exceptions, issue follow-up, and the date when the artifact was last challenged by governance.

A realistic sample for 26 pilot success metrics would include at least one discovery-science workspace, one translational-science workspace, and one regulatory-science or quality-adjacent scenario. The sample should show whether the same rule is applied differently depending on data class. Public literature summaries should have lighter evidence requirements. Restricted research content should require project-owner approval, traceability to source material, and explicit output-review responsibility. GxP-adjacent or submission-support use should require a documented boundary assessment and stronger change-control evidence.

The most useful audit evidence is not the existence of the document itself. It is the join between this document and operating records: inventory entries, project approvals, access groups, supplier clauses, monitoring logs, training completion, and examples of outputs reviewed or rejected. If those joins cannot be shown, the control may exist on paper but not operate reliably.

## Questions for walkthroughs

During walkthroughs, the audit team should ask who owns this artifact, how teams know when it applies, what happens when a pilot changes scope, where exceptions are logged, and how management knows the artifact is being followed. The team should also ask for one example where the rule stopped or changed a proposed AI use. Evidence of a controlled rejection, redesign, or escalation is often a stronger sign of governance maturity than a list of approved pilots.